Literature DB >> 1839743

Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients.

R Ridolfi1, L Amaducci, S Derni, L Fabbri, M P Innocenti, P Vignutelli.   

Abstract

The Authors report their experiences on the treatment of 13 consecutive cases of gastro-intestinal carcinoid tumors observed over the last 11 years. The primary sites were as follows: intestine (5 cases), appendix (3 cases), colon (1 case) and peritoneum (4 cases); only 3 patients presented systemic signs. Ten patients in advanced phase were treated with a chemotherapeutic regimen containing 5-fluorouracil (5-Fu) and streptozotocin (STZ). One case was excluded from the study because of a concomitant gastric carcinoma. Of the 9 evaluable patients, two achieved partial remission (22%) with a duration of 18+ and 66 months respectively; 4 (44.5%) had stable disease for periods ranging from 7 to 40 months and 3 cases progressed. Severe toxicity (thrombocytopenia and diarrhea) occurred in 2 cases and disappeared with the suspension of therapy. The systemic signs disappeared with treatment and did not appear in 2 cases out of 3. The prospective of the employment of new drugs such as alpha-interferon and, above all, somatostatin provides hope that this uncommon disease may have an improved response rate to treatment in the future.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1839743     DOI: 10.1080/1120009x.1991.11739114

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  7 in total

1.  Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.

Authors:  Katharine E H Thomas; Brianne A Voros; J Philip Boudreaux; Ramcharan Thiagarajan; Eugene A Woltering; Robert A Ramirez
Journal:  Oncologist       Date:  2019-01-11

2.  A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery.

Authors:  Toshiya Ochiai; Sosuke Komiyama; Hisashi Ikoma; Takeshi Kubota; Masayoshi Nakanishi; Daisuke Ichikawa; Shojiro Kikuchi; Hitoshi Fujiwara; Chohei Sakakura; Yukihito Kokuba; Teruhisa Sonoyama; Eigo Otsuji
Journal:  Int J Clin Oncol       Date:  2010-03-11       Impact factor: 3.402

3.  Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.

Authors:  Su-Jung Kim; Jin Won Kim; Sae-Won Han; Do-Youn Oh; Se-Hoon Lee; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

Review 4.  Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?

Authors:  Mark A Febbraio; Saskia Reibe; Shabnam Shalapour; Geraldine J Ooi; Matthew J Watt; Michael Karin
Journal:  Cell Metab       Date:  2018-11-15       Impact factor: 27.287

5.  Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group.

Authors:  Keith Stuart; Donna E Levy; Tom Anderson; Constantine A Axiotis; Janice P Dutcher; Andrew Eisenberg; John K Erban; Al Bowen Benson III
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

6.  Malignant neoplasms of the appendix.

Authors:  Mark E O'Donnell; Stephen A Badger; Garth C Beattie; Jim Carson; W Ian H Garstin
Journal:  Int J Colorectal Dis       Date:  2007-04-20       Impact factor: 2.571

7.  Streptozotocin-induced cytotoxicity, oxidative stress and mitochondrial dysfunction in human hepatoma HepG2 cells.

Authors:  Haider Raza; Annie John
Journal:  Int J Mol Sci       Date:  2012-05-11       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.